WO2005084654A3 - Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents - Google Patents

Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents Download PDF

Info

Publication number
WO2005084654A3
WO2005084654A3 PCT/US2005/006818 US2005006818W WO2005084654A3 WO 2005084654 A3 WO2005084654 A3 WO 2005084654A3 US 2005006818 W US2005006818 W US 2005006818W WO 2005084654 A3 WO2005084654 A3 WO 2005084654A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
cox
treating
combination
psychiatric disorders
Prior art date
Application number
PCT/US2005/006818
Other languages
French (fr)
Other versions
WO2005084654A2 (en
Inventor
Diane Stephenson
Duncan P Taylor
Original Assignee
Pharmacia Corp
Diane Stephenson
Duncan P Taylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Diane Stephenson, Duncan P Taylor filed Critical Pharmacia Corp
Priority to EP05724377A priority Critical patent/EP1725222A2/en
Priority to CA002556380A priority patent/CA2556380A1/en
Priority to JP2007501959A priority patent/JP2007526328A/en
Priority to BRPI0508254-4A priority patent/BRPI0508254A/en
Publication of WO2005084654A2 publication Critical patent/WO2005084654A2/en
Publication of WO2005084654A3 publication Critical patent/WO2005084654A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a novel method of treating and/or preventing psychiatric disorders in a subject by administering to the subject at last one Cox-2 inhibitor alone or in combination with one or more antidepressant agents. Compositions, pharmaceutical compositions and kits are also described.
PCT/US2005/006818 2004-03-02 2005-03-02 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents WO2005084654A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05724377A EP1725222A2 (en) 2004-03-02 2005-03-02 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
CA002556380A CA2556380A1 (en) 2004-03-02 2005-03-02 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
JP2007501959A JP2007526328A (en) 2004-03-02 2005-03-02 Methods and compositions for treating or preventing mental disorders with Cox-2 inhibitors, alone and in combination with antidepressants
BRPI0508254-4A BRPI0508254A (en) 2004-03-02 2005-03-02 methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54928104P 2004-03-02 2004-03-02
US60/549,281 2004-03-02

Publications (2)

Publication Number Publication Date
WO2005084654A2 WO2005084654A2 (en) 2005-09-15
WO2005084654A3 true WO2005084654A3 (en) 2005-11-17

Family

ID=34919463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/006818 WO2005084654A2 (en) 2004-03-02 2005-03-02 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents

Country Status (5)

Country Link
EP (1) EP1725222A2 (en)
JP (1) JP2007526328A (en)
BR (1) BRPI0508254A (en)
CA (1) CA2556380A1 (en)
WO (1) WO2005084654A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070084123A (en) * 2004-10-15 2007-08-24 엔.브이.오가논 Treatment of bipolar disorders and associated symptoms
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
JP5128578B2 (en) * 2006-04-04 2013-01-23 エモディス ゲーエムベーハー Use of κ-opioid receptor antagonist-containing compositions for the treatment of dissociative disorders
CA2704836C (en) 2007-11-28 2015-12-29 Nektar Therapeutics Oligomer-tricyclic conjugates
FR2935611B1 (en) * 2008-09-10 2010-10-15 Commissariat Energie Atomique USE OF ANTI-CONNEXINE AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC MOLECULES
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
GB0822077D0 (en) * 2008-12-03 2009-01-07 Minster Res Ltd Novel treatments
ES2859676T3 (en) * 2011-10-18 2021-10-04 Askat Inc Medicinal composition
US20150141513A1 (en) * 2012-05-10 2015-05-21 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders and neurological diseases
GB201416017D0 (en) * 2014-09-10 2014-10-22 New Royal Holloway & Bedford An Anticonvulsant Compound
WO2017213977A1 (en) * 2016-06-07 2017-12-14 Mehra Akhil Methods and compositions for the treatment of trauma and stressor-related disorders
AU2017384392B2 (en) 2016-12-20 2023-05-25 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
PL3338768T3 (en) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
JP2020525545A (en) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー Transdermal therapeutic system containing asenapine and silicone-acrylic hybrid polymer
KR20200026920A (en) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 NK-1 antagonist compositions for treating depression and methods for use in treating depression
WO2019060729A1 (en) * 2017-09-21 2019-03-28 Tremeau Pharmaceutials, Inc. An ingestible product and a method of using the same
MX2020005517A (en) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Crystal forms and production methods thereof.
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
MX2020014286A (en) 2018-06-20 2021-03-25 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine.
SG11202113266YA (en) 2019-06-04 2021-12-30 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102297A2 (en) * 2001-06-19 2002-12-27 Mueller Norbert Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102297A2 (en) * 2001-06-19 2002-12-27 Mueller Norbert Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAVARES I A ET AL: "ACEMETACIN AND INDOMETHACIN: DIFFERENTIAL INHIBITION OF CONSTITUTIVE AND INDUCIBLE CYCLO-OXYGENASES IN HUMAN GASTRIC MUCOSA AND LEUCOCYTES", INTERNATIONAL JOURNAL OF TISSUE REACTIONS, BIOSCIENCE EDIPRINT, GENEVA, CH, vol. 15, no. 2, 1993, pages 49 - 53, XP000655243, ISSN: 0250-0868 *

Also Published As

Publication number Publication date
EP1725222A2 (en) 2006-11-29
JP2007526328A (en) 2007-09-13
WO2005084654A2 (en) 2005-09-15
CA2556380A1 (en) 2005-09-15
BRPI0508254A (en) 2007-07-24

Similar Documents

Publication Publication Date Title
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
WO2005037259A3 (en) Methods and compositions for the prevention or treatment of neoplasia comprising a cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
WO2007089445A3 (en) Ang2 and vegf inhibitor combinations
WO2006073973A3 (en) Novel benzylamine derivatives as cetp inhibitors
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
CY1112238T1 (en) ANTI-KINESIN SUSPENSIONS AND METHODS OF USING THESE
WO2007092622A3 (en) Compositions and methods for treating bone
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2006028963A3 (en) Substituted heterocyclic compounds and uses thereof
MX2008011633A (en) Aminoquinolones as gsk-3 inhibitors.
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2006026747A3 (en) Diphenylethylene compounds and uses thereof
WO2007098099A3 (en) Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor
WO2004017948A3 (en) Use of lck inhibitor for treatment of immunologic diseases
WO2005023193A3 (en) Methods of treating endometriosis
WO2006028524A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
WO2006080549A3 (en) Method and composition for treating central nervous system disorders
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
TW200507840A (en) Method of treating multiple myeloma
EA200970164A1 (en) Caspase Inhibitors Based on Pyridasinone Carcass
WO2006130493A3 (en) Heterocycles useful as modulators of ion channels
TW200716561A (en) P38 inhibitors and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2556380

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/009919

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007501959

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005724377

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005724377

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0508254

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2005724377

Country of ref document: EP